Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
IMGN151-1001
AbbVie Deutschland GmbH & Co. KG
Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer
1 trial -
IMGN632-0802
AbbVie Deutschland GmbH & Co. KG
CD123 positive Acute Myeloid Leukemia
1 trial -
IMGN853-0424
AbbVie Deutschland GmbH & Co. KG
Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
1 trial -
IMMU-132-06
Gilead Sciences Pty Limited
Locally Advanced/Metastatic Urothelial Cancer
1 trial -
IMMUWHY
The George Institute
Advanced stage intrahepatic biliary tract cancer (BTC)
1 trial -
IMMUWIN
The George Institute
Intermediate stage hepatocellular carcinoma (HCC)
1 trial -
IMP1734
Eikon Therapeutics
Advanced Solid Tumor
1 trial -
IMX-110 combined with Tislelizumab
Immix Biopharma
Advanced Solid Tumor
1 trial -
IN10018
Hospital Authority, Hong Kong
Cervical Adenocarcinoma
1 trial -
INAVOLISIB
Fondazione Telethon ETS
endometrial cancer
1 trial -
INBRX-106 - Hexavalent OX40 agonist antibody
Inhibrx Biosciences
Solid Tumor
1 trial -
INBRX-109
Inhibrx Biosciences
Conventional Chondrosarcoma
1 trial -
INC280
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
1 trial -
INCB 84344-102
Incyte
Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
1 trial -
INCB099280, Adagrasib
Incyte
Advanced Solid Tumors Harboring a KRASG12C Mutation
1 trial -
INCB123667-203
Incyte
Ovarian Cancer
1 trial -
INCMGA0012-204
Incyte
Endometrial cancer, Endometrial cancer
1 trial -
INDOCYANINE GREEN
The George Institute
Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery
1 trial -
INDOCYANINE GREEN
Fondazione Telethon ETS
Patients with gynecological cancers undergoing pelvic exenteration
1 trial -
INES
Fondazione Telethon ETS
Ewing Sarcoma
1 trial -
INO-3112
INOVIO PHARMACEUTICALS, INC.
Cervical Cancer
1 trial -
INO-3112
INOVIO PHARMACEUTICALS, INC.
Head and Neck Squamous Cell Cancer
1 trial -
INO-3112 vaccine
INOVIO PHARMACEUTICALS, INC.
Uterine Cervical Neoplasms
1 trial -
INO-5401
INOVIO PHARMACEUTICALS, INC.
Urothelial Carcinoma
1 trial -
INT230-6
INTENSITY THERAPEUTICS, INC.
Breast Cancer
2 trials -
INXN-2001
Alaunos Therapeutics
Melanoma
1 trial -
IO102-IO103
IO Biotech
Melanoma
2 trials -
IO102-IO103 in combination with pembrolizumab
IO Biotech
Lung Cancer Non Small Cell
1 trial -
IOB-022/KN-D38
IO Biotech
Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
1 trial -
IONIS-STAT3Rx
IONIS PHARMACEUTICALS INC
Advanced Cancers
1 trial -
IOR-IISML42037
The George Institute
Lung Cancer
1 trial -
IOR-REG-2501
The George Institute
Cutaneous Basal Cell Carcinoma
1 trial -
IOV-3001
Iovance Biotherapeutics B.V.
Unresectable Melanoma
1 trial -
IOV-4001
Iovance Biotherapeutics B.V.
Unresectable Melanoma
1 trial -
IOV-COM-202
Iovance Biotherapeutics B.V.
Neoplasm
1 trial -
IOV-LUN-202
Iovance Biotherapeutics B.V.
Metastatic Non-Small-Cell Lung Cancer
1 trial -
IOV-MEL-202
Iovance Biotherapeutics B.V.
Previously treated advanced melanoma
1 trial -
IPC 2022-067
The George Institute
acute myeloid leukemia
1 trial -
IPC 2024-001
The George Institute
acute myeloid leukemia
1 trial -
IPH5201-201
Lacuna Pharma Pty Ltd
Non-Small Cell Lung Cancer II, III
1 trial -
IPH6501
Lacuna Pharma Pty Ltd
Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
1 trial -
IPILIMUMAB, NIVOLUMAB
Ningbo Cancer Hospital
type B3 thymoma and thymic carcinoma
1 trial -
IPN01203
Ipsen
Advanced Solid Tumor, Metastatic Solid Tumor
1 trial -
IRINOTECAN, lurbinectedin
Lacuna Pharma Pty Ltd
Selected Advanced Solid Tumors
1 trial -
IRSSP-001
The George Institute
Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.
1 trial -
IRST100.42
Istituto Gentili S.r.l.
neuroendocrine tumors, soft tissue sarcoma
1 trial -
IRST100.59
Istituto Gentili S.r.l.
Solid tumors
1 trial -
IRST100.60
Istituto Gentili S.r.l.
NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.